From: Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
SCD individualsn = 481 | |
---|---|
No. (%) with clinical progression | 70 (15%) |
Progression to MCI | 49 (10%) |
Progression to AD dementia | 10 (2%) |
Progression to non-AD dementia | 11 (2%) |
Age | 62 ± 9 |
Gender, no. (%) females | 211 (44%) |
MMSE | 28 ± 1.6 |
Follow-up duration | 3 ± 2 |
Medial temporal lobe atrophy | 0.4 ± 0.5 |
Global cortical atrophy | 0.4 ± 0.6 |
Hippocampal volume (cm3) | 7.2 ± 1 |
Normalized whole brain volume (cm3) | 1453 ± 100 |
Amyloid β1–42 | 879 ± 260 |
Total Tau | 298 ± 196 |
p-tau | 49 ± 22 |